Jan 6, 2020 Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL) Learn More
Dec 16, 2019 Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study Learn More
Dec 13, 2019 Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium Learn More